Home Cart Sign in  
Chemical Structure| 345627-80-7 Chemical Structure| 345627-80-7

Structure of SNS-032
CAS No.: 345627-80-7

Chemical Structure| 345627-80-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SNS-032 is a potent inhibitor of cyclin-dependent kinases (CDKs)9, 2 and 7 (IC50 values are 4, 38 and 62 nM respectively).

Synonyms: BMS-387032

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SNS-032

CAS No. :345627-80-7
Formula : C17H24N4O2S2
M.W : 380.53
SMILES Code : O=C(C1CCNCC1)NC2=NC=C(SCC3=NC=C(C(C)(C)C)O3)S2
Synonyms :
BMS-387032
MDL No. :MFCD09833875
InChI Key :OUSFTKFNBAZUKL-UHFFFAOYSA-N
Pubchem ID :3025986

Safety of SNS-032

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SNS-032

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK5

    CDK5/p35, IC50:340 nM

  • CDK2

    CDK2/CyclinE, IC50:48 nM

    CDK2/CyclinA, IC50:38 nM

  • CDK9

    CDK9/CyclinT, IC50:4 nM

  • CDK7

    CDK7/CyclinH, IC50:62 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Acute Myeloid Leukemia cells 50 nM 6 days To evaluate the effect of SNS-032 on the proliferation of Acute Myeloid Leukemia cells, results showed that the combination of SNS-032 with abemaciclib significantly decreased the proliferation of REL_FREE cells. PMC7140113
BRAFwt/NRASwt melanoma cells 10 μM SNS-032 showed the greatest selectivity for BRAFwt/NRASwt lines PMC8316294
22Rv1 cells 0.5 µM 24 hours SNS-032 significantly downregulated the expressions of USP1 and SIX1 PMC8990483
PC3 cells 0.5 µM 24 hours SNS-032 significantly downregulated the expressions of USP1 and SIX1 PMC8990483
PancVH1 0.5nM to 10μM 72 hours To evaluate the anti-tumor activity of SNS-032 in PancVH1 cells, results showed significant cytotoxicity of SNS-032 in KRAS mutant PancVH1 cells. PMC9481717
HPNE 0.5nM to 10μM 72 hours To evaluate the cytotoxicity of SNS-032 in HPNE cells, results showed lower toxicity of SNS-032 in normal pancreatic cells. PMC9481717
KYSE30 0.27 μM 72 hours SNS-032 significantly inhibited cell viability with an IC50 value of 0.27 μM PMC8571299
KYSE150 0.25 μM 72 hours SNS-032 significantly inhibited cell viability with an IC50 value of 0.25 μM PMC8571299
KYSE450 0.34 μM 72 hours SNS-032 significantly inhibited cell viability with an IC50 value of 0.34 μM PMC8571299
KYSE510 0.32 μM 72 hours SNS-032 significantly inhibited cell viability with an IC50 value of 0.32 μM PMC8571299
TE-1 0.28 μM 72 hours SNS-032 significantly inhibited cell viability with an IC50 value of 0.28 μM PMC8571299
MDA-MB-231 0.1 μM 72 hours To evaluate the effect of SNS-032 on cell growth, results showed that SNS-032 significantly inhibited the growth of MDA-MB-231 cells. PMC9322647
MDA-MB-468 0.2 μM 72 hours To evaluate the effect of SNS-032 on cell growth, results showed that SNS-032 significantly inhibited the growth of MDA-MB-468 cells. PMC9322647
HepG2 1 μM 6 h SNS-032 accelerated the degradation of SIX1 PMC10043269
HepG2 1 μM 18 h SNS-032 accelerated the degradation of RPS16 PMC10043269
HCT116 100 nM 24 hours Induced DR5 expression PMC10364554
HCT116 100 nM 8 hours Inhibited p73 Thr86 phosphorylation PMC10364554
MDA-MB-468 10 nmol/L 24 hours To evaluate the internalization and antitumor functions of the ADC in high EGFR-expressing cells. Results showed that the ADC exhibited rapid internalization in MDA-MB-468 cells and accumulated in acidic lysosomal clusters, indicating effective release within tumor cells. PMC9322647
CAL51 10 nmol/L 24 hours To evaluate the internalization and antitumor functions of the ADC in low EGFR-expressing cells. Results showed minimal internalization of the ADC in CAL51 cells, indicating weaker inhibitory effects on low EGFR-expressing cells. PMC11292198

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
nude mice 22Rv1 xenograft model intraperitoneal injection 30 mg/kg Twice weekly for 3 weeks SNS-032 significantly inhibited tumor growth and induced tumor cell apoptosis PMC8990483
nude mice KYSE30 xenograft model intraperitoneal injection 25 mg/kg Twice a week for 2 weeks SNS-032 significantly inhibited the growth of KYSE30 xenograft tumors, reducing tumor volume and weight PMC8571299
mice human MDA-MB-231 TNBC xenograft model intravenous injection 20 mg/kg every 2 days for 30 days To evaluate the effect of SNS-032 on tumor growth, results showed that SNS-032 significantly restricted tumor growth and enhanced human immune cell infiltration. PMC9322647
BALB/c nude mice Hep3B xenograft model intraperitoneal injection 15 mg/kg/day 3 days on/2 days off for 14 days SNS-032 significantly inhibited the growth of Hep3B xenografts PMC10043269
Nude mice HCT116 xenograft model Intraperitoneal injection 15 mg/kg once weekly for 34 days Inhibited tumor growth and induced DR5 expression and apoptosis PMC10364554
NSG mice Breast cancer xenograft model Intravenous injection 15 mg·kg−1·d−1 every other day for 21 days To evaluate the antitumor effects of the ADC in breast cancer xenograft models. Results showed that the ADC significantly inhibited the growth of MDA-MB-468 tumors without causing significant weight loss or toxicity. PMC11292198

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00292864 Tumors Phase 1 Completed - United States, Arizona ... More >> Premiere Oncology of Arizona Scottsdale, Arizona, United States, 85260 United States, California University of California Davis Medical Center Davis, California, United States, 95817 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Massachusetts General Hospital Boston, Massachusetts, United States, 02215 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT00446342 B-lymphoid Malignancies ... More >> Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Multiple Myeloma Less << Phase 1 Completed - United States, California ... More >> City of Hope Duarte, California, United States, 91010 Stanford Cancer Center Stanford, California, United States, 94305 United States, Georgia Winship Cancer Institute at Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Greenebaum Cancer Center, University of Maryland Baltimore, Maryland, United States, 21201 United States, New Jersey Hackensack University Medical Center at the Cancer Center Hackensack, New Jersey, United States, 07601 United States, Texas MD Anderson Cancer Center, University of Texas Houston, Texas, United States, 77230 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.14mL

2.63mL

1.31mL

26.28mL

5.26mL

2.63mL

References

 

Historical Records

Categories